BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24311642)

  • 1. The legend of cytomegalovirus and glioblastoma lives on.
    Weller M; Soffietti R; Brada M
    Neuro Oncol; 2014 Jan; 16(1):166. PubMed ID: 24311642
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenging cytomegalovirus data in glioblastoma.
    Wick W; Wick A; Platten M
    Neuro Oncol; 2014 Jan; 16(1):165. PubMed ID: 24353326
    [No Abstract]   [Full Text] [Related]  

  • 3. Does valganciclovir have a role in glioblastoma therapy?
    Cobbs CS
    Neuro Oncol; 2014 Mar; 16(3):330-1. PubMed ID: 24523453
    [No Abstract]   [Full Text] [Related]  

  • 4. CMV infection and glioma, a highly controversial concept struggling in the clinical arena.
    Wick W; Platten M
    Neuro Oncol; 2014 Mar; 16(3):332-3. PubMed ID: 24523454
    [No Abstract]   [Full Text] [Related]  

  • 5. Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas?
    Wen PY
    Neuro Oncol; 2014 Mar; 16(3):329. PubMed ID: 24523452
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival in patients with glioblastoma receiving valganciclovir.
    Söderberg-Nauclér C; Rahbar A; Stragliotto G
    N Engl J Med; 2013 Sep; 369(10):985-6. PubMed ID: 24004141
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain cancer. A viral link to glioblastoma?
    Miller G
    Science; 2009 Jan; 323(5910):30-1. PubMed ID: 19119195
    [No Abstract]   [Full Text] [Related]  

  • 8. [Questionable effect of antiviral therapy in malignant brain tumors].
    Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
    Lakartidningen; 2014 Apr 29-May 13; 111(18-19):809. PubMed ID: 24855749
    [No Abstract]   [Full Text] [Related]  

  • 9. [Inconclusive data].
    Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
    Lakartidningen; 2014 Jul 2-15; 111(27-28):1192. PubMed ID: 25162111
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.
    Stragliotto G; Rahbar A; Solberg NW; Lilja A; Taher C; Orrego A; Bjurman B; Tammik C; Skarman P; Peredo I; Söderberg-Nauclér C
    Int J Cancer; 2013 Sep; 133(5):1204-13. PubMed ID: 23404447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus.
    Drew WL; Liu C
    Clin Transplant; 2012; 26(6):949-52. PubMed ID: 22774759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underdosing of prophylactic valganciclovir due to inaccurate estimation of glomerular filtration rate leading to severe cytomegalovirus disease in a kidney transplant recipient.
    Penne EL; Nurmohamed SA
    Antimicrob Agents Chemother; 2014; 58(2):1271-2. PubMed ID: 24470493
    [No Abstract]   [Full Text] [Related]  

  • 14. New prophylactic treatment strategy for cytomegalovirus disease.
    Lake KD
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S13-6. PubMed ID: 14686230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
    Humar A; Siegal D; Moussa G; Kumar D
    J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
    Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
    Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
    Razonable RR; Paya CV
    Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valganciclovir in patients with glioblastoma.
    Hellstrand K; Martner A; Bergström T
    N Engl J Med; 2013 Nov; 369(21):2066. PubMed ID: 24256397
    [No Abstract]   [Full Text] [Related]  

  • 19. Valganciclovir in patients with glioblastoma.
    Söderberg-Nauclér C; Peredo I; Stragliotto G
    N Engl J Med; 2013 Nov; 369(21):2066-7. PubMed ID: 24256396
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies.
    Nassetta L; Kimberlin D; Whitley R
    J Antimicrob Chemother; 2009 May; 63(5):862-7. PubMed ID: 19287011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.